Literature DB >> 22870479

'Old drugs for new applications': can orthopedic research benefit from this strategy?

Xiaohua Pan1, Wenxiang Cheng, Jiali Wang, Ling Qin, Yuxiao Lai, Jian Tang, Peng Shang, Peigen Ren, Peng Zhang.   

Abstract

New drug exploration is difficult in a clinical setting and the development of new drugs may be costly and time consuming. With further research into the pathological mechanisms and etiology of diseases as well as the rapid development of biological techniques, many 'old drugs' that have been applied in clinics may have new therapeutic functions which may shed light on clinical management. Based on this, we have investigated the 'old drugs for new applications' strategy in pharmacology which may be less expensive and more efficient in the clinical setting. In this paper we have explored and illustrated the potential applications of 'old drugs' for the treatment of orthopedic diseases, especially in arthritis and osteoporosis therapy.

Entities:  

Keywords:  cholinergic anti-inflammatory pathway; cholinergic antinociceptive pathway; old drugs for new applications; orthopedic research; rheumatoid arthritis

Year:  2011        PMID: 22870479      PMCID: PMC3382676          DOI: 10.1177/1759720X11408487

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  39 in total

Review 1.  The inflammatory reflex.

Authors:  Kevin J Tracey
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

2.  "Old drugs" for the treatment of rheumatoid arthritis: will the cholinergic anti-inflammatory pathway and anti-nociceptive pathway work?

Authors:  Xiaohua Pan; Xiaowei Yu; Ling Qin; Peng Zhang
Journal:  Inflamm Res       Date:  2010-09-17       Impact factor: 4.575

3.  Aspirin to prevent colorectal cancer: time to act?

Authors:  Robert Benamouzig; Bernard Uzzan
Journal:  Lancet       Date:  2010-10-21       Impact factor: 79.321

4.  Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway.

Authors:  Wouter J de Jonge; Esmerij P van der Zanden; Frans O The; Maarten F Bijlsma; David J van Westerloo; Roelof J Bennink; Hans-Rudolf Berthoud; Satoshi Uematsu; Shizuo Akira; Rene M van den Wijngaard; Guy E Boeckxstaens
Journal:  Nat Immunol       Date:  2005-07-17       Impact factor: 25.606

5.  Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations.

Authors:  G E Gutierrez; D Lalka; I R Garrett; G Rossini; G R Mundy
Journal:  Osteoporos Int       Date:  2006-05-03       Impact factor: 4.507

6.  Erythromycin inhibits wear debris-induced inflammatory osteolysis in a murine model.

Authors:  Weiping Ren; Bin Wu; Xin Peng; Lois Mayton; Dongzi Yu; Juanjie Ren; Ben D Chen; Paul H Wooley
Journal:  J Orthop Res       Date:  2006-02       Impact factor: 3.494

7.  Effect of oral erythromycin therapy in patients with aseptic loosening of joint prostheses.

Authors:  Weiping Ren; Ralph Blasier; Xin Peng; Tong Shi; Paul H Wooley; David Markel
Journal:  Bone       Date:  2008-12-29       Impact factor: 4.398

Review 8.  New therapeutic approaches for the treatment of rheumatoid arthritis may rise from the cholinergic anti-inflammatory pathway and antinociceptive pathway.

Authors:  Xiao Hua Pan; Jianxin Zhang; Xiaowei Yu; Ling Qin; Ligeng Kang; Peng Zhang
Journal:  ScientificWorldJournal       Date:  2010-11-16

Review 9.  The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).

Authors:  W R Kem
Journal:  Behav Brain Res       Date:  2000-08       Impact factor: 3.332

10.  Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation.

Authors:  Hong Wang; Man Yu; Mahendar Ochani; Carol Ann Amella; Mahira Tanovic; Seenu Susarla; Jian Hua Li; Haichao Wang; Huan Yang; Luis Ulloa; Yousef Al-Abed; Christopher J Czura; Kevin J Tracey
Journal:  Nature       Date:  2002-12-22       Impact factor: 49.962

View more
  1 in total

1.  Selective killing effect of oxytetracycline, propafenone and metamizole on A549 or Hela cells.

Authors:  Jinhui Shao; Guihua Feng
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.